1, For advanced NSCLC patients with negative EGFR or unclear status, first-line treatment should still be a third-generation chemotherapy regimen such as Kinzel. 2, For older patients with advanced NSCLC with good PS score, carboplatin-based two-drug combination is better than single agent. 3.Maintenance therapy needs to be carried out in patients with good PS scores, and Kinzel is an effective regimen for maintenance therapy, and Lipitor is still unsurpassed in non-squamous cancer patients. 4.Targeted drugs for adjuvant therapy cannot prolong OS and DFS, chemotherapy is still the choice of adjuvant therapy for patients with good PS score. 5.Lipitide/carboplatin and lipitide/cisplatin synchronous radiotherapy for locally advanced NSCLC are well tolerated, and data from global randomized controlled phase III clinical studies are expected.